Shortfalls threaten Medicaid and Medicare programs

Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.

340B discounts preclude rebates paid to pharmacy benefit managers for their payer clients. Dunn says new transparency and cost pressures have created awareness of “340B rebate erosion.”

Onswik is approved to improve glycemic control in adults with Type 2 diabetes and will be available in the United States in the coming months in two concentrations. No information is available on the list price.

A meta-analysis of 13 trials and 969 patients saw some short-term reductions in cancer-related pain and anxiety, especially during procedures, when using virtual reality.

Chad Hatfield, Pharm.D., M.H.A., BCPS, vice president and chief pharmacy officer of UC Davis Health, says pharmacists are embedded in “nearly all specialties," with more than 150 holding board certification.

A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability

8-year data show adjuvant Tagrisso boosts survival after surgery for EGFR-mutated NSCLC, reshaping early Lung Cancer care and adherence.

Sova, a clinical advisor for Employers Health, expects more employers to exclude GLP-1s for obesity but urges a look at coverage for specific cardiometabolic conditions.